Mariana Oncology is developing targeted radiopharmaceuticals for the treatment of high unmet need solid tumors. Access co-incubated Mariana, and invested in its Series A financing announced in December 2021.
Location: United States, Massachusetts, Woburn
Total raised: $175M
Investors 3
| Date | Name | Website |
| - | Access Bio... | accessbio-... |
| - | Forbion | forbion.co... |
| 18.12.2022 | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.09.2023 | Series B | $175M | - |
Mentions in press and media 11
| Date | Title | Description |
| 30.06.2025 | Forbion Announces Fifth Exit from Forbion Growth Opportunities Fund II with the Sale of Capstan Therapeutics to AbbVie for USD 2.1 Billion | • Capstan sale ranks as the largest ever payment for an early-stage private biotech company by upfront consideration value and is Forbion’s seventh consecutive >$1B exit. • Capstan’s in vivo CAR-T platform offers a first-in-class approac... |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 08.12.2024 | Atlas Venture: $450 Million Fund XIV Closed To Invest In Biotech Innovation | Atlas Venture—a leading early-stage venture capital firm investing in biotech innovation—announced closing its fourteenth fund, raising $450 million in an oversubscribed fundraise. Through Fund XIV, Atlas Venture will continue collaborating... |
| 15.10.2024 | Forbion raises in excess of €2 billion for two new funds | • Forbion’s largest fundraising to date, with Forbion’s Growth Opportunities Fund III raising €1.2 billion and Forbion Ventures Fund VII raising €890 million • Assets under management now at €5 billion • Fundraising follows strong performan... |
| 31.05.2024 | Forbion's Billion-Dollar Sale to Johnson & Johnson: A Landmark Achievement in Biotech Innovation | The recent announcement of Forbion's sale of Yellow Jersey Therapeutics to Johnson & Johnson for a staggering $1.25 billion has sent shockwaves through the biotech industry. This monumental deal, which includes the acquisition of rights... |
| 28.05.2024 | Forbion Announces $1.25 Billion Sale to Johnson & Johnson of Numab Therapeutics Subsidiary, Including Rights to NM26, a Bi-specific Antibody for the Treatment of Atopic Dermatitis, Marking its Six... | • Forbion announces the sale of Yellow Jersey Therapeutics, a wholly owned subsidiary to be spun off from its portfolio company Numab Therapeutics, an investment of Forbion’s Growth Opportunities Fund I • This is Forbion's sixth consecutive... |
| 02.05.2024 | Forbion Portfolio Company Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer | • Latest deal marks the fifth Forbion portfolio company to be acquired for over $1 bn within a year Naarden, The Netherlands, 2 May 2024 - Forbion portfolio company Mariana Oncology (Mariana) is to be acquired by Novartis for $1 billion in ... |
| 03.04.2024 | From generative chemistry to computational astrophysics, startups employ new methods to fight cancer | Here are a few startups in the cancer space that made headlines recently The recent revelation of Princess Kate Middleton’s battle with cancer has sent ripples across the globe, reminding us that this disease knows no boundaries of status o... |
| 07.09.2023 | Eli Lilly hops aboard for Mariana Oncology's $175M series B, radiopharmaceuticals mission | Investors have dived deep into their wallets for Mariana Oncology’s series B financing, with Eli Lilly coming aboard for the oversubscribed $175 million round aimed at making waves in radiopharmaceutical development. Deep Track Capital and ... |
| 07.09.2023 | Mariana Oncology Raises USD175M in Series B Funding | Mariana Oncology, a Watertown MA-based fully integrated, next-generation radiopharmaceuticals company, raised $175m in Series B financing. The round was co-led by Forbion (the first investment by its Forbion Ventures Fund VI,) and Deep Trac... |
Show more